查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1563373

肺癌治疗市场规模、份额、成长分析、按癌症类型、按地区划分 - 产业预测，2024-2031 年

Lung Cancer Therapeutics Market Size, Share, Growth Analysis, By Cancer Type (Non-small cell lung cancer, and Small cell lung cancer), By Region - Industry Forecast 2024-2031
出版日期: | 出版商: SkyQuest | 英文 242 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年全球肺癌治疗市场规模约322亿美元，预测期间（2024-2031年）复合年增长率为13.2%，从2023年的约364亿美元上升至2031年的868亿美元预计将达到10亿美元。

由于肺癌发病率上升、医疗技术进步以及人们对癌症早期检测的认识不断增强，全球肺癌治疗市场正在经历强劲增长。人口老化、生活方式改变和吸烟盛行等多种因素导致肺癌患者数量增加，对有效治疗解决方案的需求不断增加。透过引入标靶治疗、免疫疗法和个人化医疗等创新疗法，市场正在不断扩大，这些疗法在改善患者治疗效果方面显示出了希望。该市场的主要企业正致力于扩大产品平臺并获得新药核准，以满足不断增长的需求。生物标记的使用、基因检测的增加以及基因疗法等新治疗方法的开发正在重塑肺癌治疗的模式。此外，製药公司和研究机构之间的合作正在推动新治疗方法的研究，并扩大各个地区获得先进疗法的机会。然而，高昂的治疗成本、严格的监管以及治疗副作用的风险继续对市场成长构成挑战。按地区划分，由于医疗保健支出高、基础设施先进以及大型製药公司的存在，北美占据了很大的市场占有率。然而，由于医疗保健服务的改善和癌症研究投资的增加，亚太地区的新兴经济体正在经历快速成长。在治疗方法创新、改进的诊断方法和活性化宣导活动的支持下，该市场预计将保持其成长轨迹，以促进早期诊断和治疗依从性。

目录

介绍

  • 研究目的
  • 定义
  • 市场范围

调查方法

  • 资讯采购
  • 二手资料来源和主要资料来源
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 市场概况展望
  • 供需趋势分析
  • 按细分市场的机会分析

市场动态及展望

  • 市场动态
    • 促进因素
    • 机会
    • 抑制因素
    • 任务
  • 波特的分析

主要市场考察

  • 关键成功因素
  • 竞争程度
  • 主要投资机会
  • 市场生态系统
  • 监管分析
  • 专利分析
  • 价格分析
  • 案例研究分析
  • 技术分析

肺癌治疗市场：依治疗分类

  • 市场概况
  • 标靶治疗
    • Bevacizumab
    • Dabrafenib/曲美替尼
    • Erlotinib
    • Osimertinib
    • 其他的
  • 免疫疗法
    • Durvalumab
    • 纳武单抗
    • Atezolizumab
    • Pembrolizumab
  • 化疗

肺癌治疗市场：依癌症类型分类

  • 市场概况
  • 非小细胞肺癌（NSCLC）
  • 小细胞肺癌（SCLC）

肺癌治疗市场：依分销管道分类

  • 市场概况
  • 医院药房
  • 零售药房
  • 网路药房
  • 其他的

肺癌治疗市场规模：依地区划分

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲国家地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • 其他中东/非洲地区

竞争格局

  • 前5名企业对比
  • 主要企业市场定位（2023年）
  • 主要市场参与者所采取的策略
  • 近期市集活动
  • 主要企业市场占有率（2023年）

主要企业简介

  • Genentech（F. Hoffmann-La Roche Ltd）
  • Eli Lilly and Company
  • Celgene Corporation
  • AstraZeneca
  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Astellas Pharma Inc.
  • Bristol Myers Squibb
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Millennium Pharmaceuticals, Inc.（Takeda）
  • Merck Sharp & Dohme Corp.
  • Eisai Co., Ltd.
  • Johnson & Johnson
  • Bayer AG
  • GlaxoSmithKline plc
  • Amgen Inc.
  • Spectrum Pharmaceuticals, Inc.
简介目录
Product Code: SQMIG35J2088

Global Lung Cancer Therapeutics Market size was valued at around 32.2 billion in 2022 and is expected to rise from USD 36.4 billion in 2023 to reach a value of USD 86.8 billion by 2031, at a CAGR of 13.2% over the forecast period (2024-2031).

The global lung cancer therapeutics market has been experiencing robust growth due to the rising incidence of lung cancer, advances in medical technology, and increasing awareness regarding early cancer detection. A combination of factors, including an aging population, lifestyle changes, and the prevalence of smoking, has contributed to the increased number of lung cancer cases, driving the demand for effective therapeutic solutions. The market has expanded through the introduction of innovative therapies such as targeted treatments, immunotherapies, and personalized medicines, which have shown promise in improving patient outcomes. Key players in the market are focusing on enhancing their product pipelines and securing regulatory approvals for new drugs to cater to the growing demand. The increasing use of biomarkers, genetic testing, and the development of new treatment modalities, such as gene therapy, are reshaping the landscape of lung cancer treatment. Moreover, collaborations between pharmaceutical companies and research institutions are driving research into novel treatments and expanding access to advanced therapies across different regions. However, the high cost of treatment, stringent regulatory frameworks, and the risk of adverse effects from therapies continue to challenge market growth. Geographically, North America holds a significant market share, driven by high healthcare expenditure, advanced infrastructure, and the presence of major pharmaceutical companies. However, emerging economies in Asia-Pacific are witnessing rapid growth due to improving healthcare access and growing investments in cancer research. The market is expected to continue its growth trajectory, supported by ongoing innovation in treatment methods, improved diagnostics, and increasing awareness campaigns promoting early diagnosis and treatment adherence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Therapeutics Market Segmental Analysis

Global Lung Cancer Therapeutics Market is segmented by Therapy, Cancer Type, Distribution Channel, and region. Based on Therapy, the market is segmented into Targeted Therapy (Bevacizumab, Dabrafenib/Trametinib, Erlotinib Hydrochloride, Osimertinib, Others), Immunotherapy (Durvalumab, Nivolumab, Atezolizumab, Pembrolizumab), Chemotherapy. Based on Cancer Type, the market is segmented into Non-small cell lung cancer (NSCLC), and Small cell lung cancer (SCLC). Based on Distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Lung Cancer Therapeutics Market

One of the primary drivers of the lung cancer therapeutics market is the rapid advancement in immunotherapy treatments. Immunotherapies, such as immune checkpoint inhibitors (e.g., Keytruda and Opdivo), have revolutionized the approach to treating non-small cell lung cancer (NSCLC) by harnessing the body's immune system to target and eliminate cancer cells. These treatments have demonstrated higher efficacy and longer survival rates compared to traditional chemotherapies. The success of immunotherapy in clinical trials has led to its increasing adoption in treatment regimens, especially for patients with advanced or metastatic lung cancer. Furthermore, ongoing research is exploring combination therapies, where immunotherapy is paired with chemotherapy or targeted therapy to enhance treatment efficacy. The growing acceptance of immunotherapy is supported by regulatory approvals and healthcare providers' recognition of its potential to offer more personalized, effective treatments. As more breakthroughs emerge, the global lung cancer therapeutics market is set to benefit from this continued momentum.

Restraints in the Global Lung Cancer Therapeutics Market

A significant restraint in the global lung cancer therapeutics market is the exorbitant cost of advanced treatments, particularly immunotherapies and targeted therapies. While these innovative therapies offer significant benefits in terms of improved patient outcomes, their high price tags make them inaccessible to a large portion of the population, especially in low- and middle-income countries. The cost of treatment can run into tens of thousands of dollars per cycle, placing a substantial financial burden on both healthcare systems and patients. Even in developed countries, where healthcare insurance may cover some of the expenses, out-of-pocket costs can still be prohibitive for many patients. The lack of affordable options exacerbates disparities in access to life-saving treatments, making cost a major barrier to market expansion. Additionally, the need for prolonged therapy in some cases further drives up overall treatment costs, limiting the broader adoption of advanced therapeutics and impeding the market's growth potential.

Market Trends of the Global Lung Cancer Therapeutics Market

An emerging trend in the lung cancer therapeutics market is the increasing use of biomarker-driven therapies, which are designed based on specific genetic and molecular characteristics of a patient's tumor. Biomarkers such as EGFR mutations, ALK rearrangements, and PD-L1 expression have become pivotal in guiding treatment decisions, particularly in the case of targeted therapies and immunotherapies. Personalized medicine, driven by biomarker identification, allows for the development of treatments tailored to the individual genetic profiles of patients, improving the chances of treatment success and minimizing adverse effects. This trend is further supported by advances in diagnostic technologies that enable quicker and more accurate biomarker detection. As pharmaceutical companies and research institutions continue to invest in biomarker-based research, the market is witnessing a shift toward more precise, individualized treatment approaches. This trend is expected to gain momentum as regulatory bodies approve more therapies linked to specific biomarkers, broadening the therapeutic landscape for lung cancer patients.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factor
  • Degree of Competition
  • Top Investment Pockets
  • Ecosystem of the Market
  • Regulatory Analysis
  • Patent Analysis
  • Pricing Analysis
  • Case Study Analysis
  • Technology Analysis

Lung Cancer Therapeutics Market, By Therapy

  • Market Overview
  • Targeted Therapy
    • Bevacizumab
    • Dabrafenib/Trametinib
    • Erlotinib Hydrochloride
    • Osimertinib
    • Others
  • Immunotherapy
    • Durvalumab
    • Nivolumab
    • Atezolizumab
    • Pembrolizumab
  • Chemotherapy

Lung Cancer Therapeutics Market, By Cancer Type

  • Market Overview
  • Non-small cell lung cancer (NSCLC)
  • Small cell lung cancer (SCLC)

Lung Cancer Therapeutics Market, By Distribution Channel

  • Market Overview
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Lung Cancer Therapeutics Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Genentech (F. Hoffmann-La Roche Ltd)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celgene Corporation
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Millennium Pharmaceuticals, Inc. (Takeda)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck Sharp & Dohme Corp.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eisai Co., Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Spectrum Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments